Drug Trial Radar · NCT07180511
A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.
Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
460
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
May 18, 2027
Study completion Jul 19, 2027
Sponsor
- Lead sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
Conditions
- Atopic Dermatitis (AD)
Interventions
10mg QY201 Placebo tabletDrug
10mg QY201 Placebo tablet
20mg QY201 Placebo tabletDrug
20mg QY201 Placebo tablet
10mg QY201 tabletDrug
10mg QY201 tablet
20mg QY201 tabletDrug
20mg QY201 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who achieved EASI-75 at week 16 of treatment.Time frame: At week 16 of treatment
- The proportion of subjects who achieved vIGA-AD 0/1 with a reduction of ≥2 points from baseline at week 16 of treatment.Time frame: At week 16 of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
EnitiateBioPharma
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.